Aditxt to acquire Appili Therapeutics

03 Apr 2024
www.pharmaceutical-technology.com
VaccineAcquisition
Aditxt to acquire Appili Therapeutics
Preview
Source: Pharmaceutical Technology
The acquisition enhances the portfolio of Aditxt in precision diagnostics and infectious disease treatment. Credit: Gorodenkoff / Shutterstock.com.
Aditxt has announced a definitive agreement under which its subsidiary, Adivir, will acquire complete issued and outstanding Class A common shares of biopharmaceutical company Appili Therapeutics.
The move enhances Aditxt’s portfolio and creates synergies with its existing programmes, particularly in precision diagnostics.
Founded in 2015, Appili developed the Food and Drug Administration-approved LIKMEZ (ATI-1501).
LIKMEZ is a reformulated version of the antibiotic metronidazole that improves patient experience and compliance by making the medication easier to swallow and better tasting.
Appili licensed the manufacturing and commercialisation rights of the product in the US and other selected territories to Saptalis Pharmaceuticals.
See Also:
Forma Therapeutics gets grant for USP30 inhibitorUSP30 inhibitor compounds for medical use
Aditxt to acquire Appili Therapeutics
Preview
Source: Pharmaceutical Technology
Dyne Therapeutics gets grant for muscle-targeting complex inhibiting DUX4 expression with oligonucleotide payload
Aditxt to acquire Appili Therapeutics
Preview
Source: Pharmaceutical Technology
Appili is also advancing ATI-1701, a live attenuated vaccine for Francisella tularensis.
The US Department of Defense has supported the ATI-1701 biodefence programme with $14m non-dilutive funding to progress the vaccine’s development.
Another key asset in Appili’s portfolio is ATI-1801, a topical formulation for cutaneous leishmaniasis.
The product, which contains paromomycin, offers a more patient-friendly treatment option for this painful and disfiguring disease.
The acquisition will aid Aditxt in bolstering its portfolio and integrating precision diagnostics with tailored treatment strategies.
The closure of the acquisition will occur in the third quarter of 2024.
Aditxt co-founder, chairman and CEO Amro Albanna stated: “The acquisition of Appili would represent another step in Aditxt’s journey towards advancing promising innovations in health.
“Our mission is to accelerate some of the most promising health innovations, like those developed by Appili, to reach their full potential and to have a lasting impact.
“By integrating Appili’s proven expertise and diverse portfolio in the infectious disease and biodefence domain, Aditxt can substantially contribute to advancing public health solutions.”
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
Targets
Drugs
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.